Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.

Atropine 0.05% effective in delaying myopia progression in children

01 Aug 2018

Treatment with atropine eye drops confers concentration-dependent myopia control effects in children, according to the results of the LAMP* trial. Specifically, the 0.05% concentration shows superiority in controlling spherical equivalent (SE) progression and axial length (AL) elongation over a 1-year follow-up as compared with the 0.025% and 0.01% concentrations.

A total of 438 children aged 4–12 years with myopia of at least −1.0 dioptre (D) and astigmatism of −2.5 D or less were randomized (1:1:1:1) to receive atropine eye drop at 0.05%, 0.025% or 0.01% or placebo eye drop once nightly to both eyes for 12 months. Cycloplegic refraction, AL, accommodation amplitude, pupil diameter and best-corrected visual acuity were assessed at baseline, week 2, and months 4, 8 and 12. Visual Function Questionnaire was administered at the end of treatment at 1 year.

Respective mean changes in SE and AL at 1 year, the primary study endpoint, were −0.27 D and 0.20 mm in the 0.05% atropine group, −0.46 D and 0.29 mm in the 0.025% group, −0.59 D and 0.36 mm in the 0.01% group, and −0.81 D and 0.41 mm in the placebo group (p<0.001). Corresponding reduction in accommodation amplitude were 1.98, 1.61, 0.26 and 0.32 D (p<0.001).

Pupil sizes under photopic and mesopic conditions increased respectively by 1.03 and 0.58 mm in the 0.05% atropine group, 0.76 and 0.43 mm in the 0.025% group, 0.49 and 0.23 mm in the 0.01% group, and 0.13 and 0.02 mm in the placebo group (p<0.001).

Visual acuity and vision-related quality of life were not affected in all treatment groups.

LAMP demonstrates that low-concentration atropine eye drops (0.05%, 0.025% and 0.01%) delay myopia in a concentration-dependent fashion, researchers said. Moreover, all atropine concentrations are well tolerated without apparent adverse effect on the quality of life.

Additional studies are warranted to explore the antimyopia mechanism of low-concentration atropine.

*Low-Concentration Atropine for Myopia Progression

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.